Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 12;5(4):599-603.
doi: 10.34067/KID.0000000000000384. Online ahead of print.

Association of Ratio of eGFR by Cystatin C and Creatinine with Mortality in Heart Failure

Bethany Roehm  1 , Meredith McAdams  1 , Jonathan Gordon  2 , Justin L Grodin  3 , S Susan Hedayati  1   4
Affiliations

Association of Ratio of eGFR by Cystatin C and Creatinine with Mortality in Heart Failure

Bethany Roehm et al. Kidney360. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.L. Grodin reports the following: Consultancy: Alexion, AstraZeneca, Eidos/BridgeBio, Pfizer, and Sarepta; and Research Funding: Eidos/BridgeBio, NIH/NHLBI, and Pfizer. S.S. Hedayati holds the Lina Obeid Chair in Biomedical Sciences at Stony Brook University, Renaissance School of Medicine. B. Roehm reports the following: Ownership Interest: Amazon and Tesla. All remaining authors have nothing to disclose.

Figures

Figure 1
Figure 1
Distribution of eGFRcys minus eGFRcr histogram showing the distribution of the difference between baseline eGFRcys and baseline eGFRcr at the intraindividual level. Negative values indicate an eGFRcys that is lower than eGFRcr. eGFRcr, creatinine-based eGFR; eGFRcys, cystatin C–based eGFR.
Figure 2
Figure 2
Survival by eGFR Category. Kaplan–Meier survival curves for (A) eGFRcr, (B) eGFRcys, (C) eGFRcr-cys, and (D) eGFRcys/eGFRcr with corresponding number at risk. P values from the log-rank test for trend are shown. Pairwise comparisons between groups were performed and significant values are represented with *P < 0.01, **P = 0.001. P values were adjusted using the Holm's adjustment method. eGFRcr-cys, eGFR using weighted average of creatinine and cystatin C.
See this image and copyright information in PMC

References

    1. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469. doi:10.1093/eurheartj/eht386 - DOI - PubMed
    1. Ivey-Miranda JB Inker LA Griffin M, et al. . Cystatin C and muscle mass in patients with heart failure. J Card Fail. 2021;27(1):48–56. doi:10.1016/j.cardfail.2020.07.013 - DOI - PMC - PubMed
    1. Farrington DK, Surapaneni A, Matsushita K, Seegmiller JC, Coresh J, Grams ME. Discrepancies between cystatin C-based and creatinine-based eGFR. Clin J Am Soc Nephrol. 2023;18(9):1143–1152. doi:10.2215/CJN.0000000000000217 - DOI - PMC - PubMed
    1. Pinsino A Carey MR Husain S, et al. . The difference between cystatin C- and creatinine-based estimated GFR in heart failure with reduced ejection fraction: insights from PARADIGM-HF. Am J Kidney Dis. 2023;82(5):521–533. doi:10.1053/j.ajkd.2023.03.005 - DOI - PubMed
    1. Aaronson KD Stewart GC Pagani FD, et al. .; REVIVAL Investigators. Registry evaluation of vital information for VADs in ambulatory Life (REVIVAL): rationale, design, baseline characteristics, and inclusion criteria performance. J Heart Lung Transplant. 2020;39(1):7–15. doi:10.1016/j.healun.2019.09.008 - DOI - PMC - PubMed